70.57USD+5.03%Mkt Cap: 3.02B USDP/E: —Last update: 2026-05-26
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individ…
Industry Peers
Diagnostics & Research166.94BUSDP/E 24.7
122.72BUSDP/E 33.6
44.05BUSDP/E 41.1
34.42BCHFP/E 37.9
33.46BUSDP/E 43.3
32.69BUSDP/E 25.5
28.46BUSD—
27.28BUSDP/E 20.3
Indicators:|
Key Statistics
Company
Market Cap3.02B USD
Enterprise Value2.14B USD
Revenue (TTM)156.12M USD
Gross Profit-62.57M USD
Net Income (TTM)-408.35M USD
Revenue/Share4.072 USD
Last Price70.57 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees910
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.39
PEG—
EV/EBITDA-5.94
EV/Revenue13.71
P/S18.65
P/B1.12
EPS (TTM)-10.30
EPS (Forward)-9.18
52W Range
29.9546% of range118.84
52W High118.84 USD
52W Low29.95 USD
Profitability
Gross Margin-42.52%
Oper. Margin-332.88%
EBITDA Margin-230.91%
Profit Margin-277.47%
ROE-15.84%
ROA-13.97%
Growth
Revenue Growth28.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-299.01M USD
CapEx (TTM)909.00K USD
FCF Margin-69.02%
FCF Yield-3.56%
Net Debt-772.08M USD
Net Debt/EBITDA2.14
Balance Sheet
Debt/Equity0.02
Current Ratio11.74
Quick Ratio11.29
Book Value/Sh60.79 USD
Cash/Share19.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)66.86 USD
Target Range56.00 USD – 80.00 USD
# Analysts7
Ownership
Shares Out.42.92M
Float33.69M
Insiders4.72%
Institutions83.63%
Short Interest
Short Ratio9.3d
Short % Float16.54%
Short % Out.16.26%
Shares Short6.98M
Short (prev mo.)7.16M
Technical
SMA 5053.20 (+32.7%)
SMA 20068.55 (+2.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)574.98K
Avg Vol (10d)558.01K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—